| Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript |
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Elizabeth Kolsky - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Nautilus First Quarter 2025 earnings conference call. |
seekingalpha.com |
2025-04-29 17:01:03 |
Czytaj oryginał (ang.) |
| Nautilus: Trading Below An Albeit Lower Net Cash Figure |
Nautilus Biotechnology, Inc. faces reflexivity risks and macroeconomic challenges, but its commercial plan starts next year with substantial cash reserves. Trading below cash value, Nautilus' patents and bio-informatics platform are not being given too much credit by markets. Although, they seem to expect that company to be minimally viable once they have an additional $30 million of cash, which still may not be enough depending on commercial costs. |
seekingalpha.com |
2025-02-28 20:59:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call Transcript |
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Will Ortmayer - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Nautilus Fourth Quarter and Full Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-28 09:25:38 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award |
Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging |
globenewswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference |
SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference. |
globenewswire.com |
2024-10-30 10:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript |
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder and Chief Executive Officer Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Operator Good day everyone, and thank you for standing by and welcome to Nautilus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-10-29 15:17:06 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript |
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tycho Peterson - Jefferies Dan Brennan - TD Cowen Operator Good day and thank you for standing by and welcome to Nautilus Q2 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. |
seekingalpha.com |
2024-07-30 19:16:09 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology Reports Second Quarter 2024 Financial Results |
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. |
globenewswire.com |
2024-07-30 12:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024 |
SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024. |
globenewswire.com |
2024-07-09 12:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know |
Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-05-03 17:01:14 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript |
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Q1 2024 Earnings Conference Call. |
seekingalpha.com |
2024-04-30 17:19:08 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology Reports First Quarter 2024 Financial Results |
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. |
globenewswire.com |
2024-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024 |
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. |
globenewswire.com |
2024-04-11 12:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript |
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-02-28 15:13:04 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results |
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. |
globenewswire.com |
2024-02-28 10:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference |
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference. |
globenewswire.com |
2024-02-22 10:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 |
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024. |
globenewswire.com |
2024-02-07 10:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award |
Society award recognizes Dr. Mallick's decades of innovative leadership and science advancing the field of computational proteomics Society award recognizes Dr. Mallick's decades of innovative leadership and science advancing the field of computational proteomics |
globenewswire.com |
2023-11-30 10:00:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development |
Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome |
globenewswire.com |
2023-11-01 10:05:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript |
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carrie Mendivil - IR Sujal Patel - Co-Founder & CEO Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - CFO Conference Call Participants Yuko Oku - Morgan Stanley Daniel Brennan - Cowen Ivy Kozlowski - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2023-10-31 13:22:10 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology Reports Third Quarter 2023 Financial Results |
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023. |
globenewswire.com |
2023-10-31 10:05:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023 |
SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023. |
globenewswire.com |
2023-10-11 12:05:00 |
Czytaj oryginał (ang.) |
| Nautilus Biotechnology to Participate in Upcoming August Investor Conferences |
SEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences: |
globenewswire.com |
2023-08-04 12:00:00 |
Czytaj oryginał (ang.) |